Lupin to Use Honeywell's HFO Technology in Inhalers, Reducing Carbon Emissions by Up to 99.9%
Global pharma major Lupin Limited announced its plan to use Honeywell’s Solstice® Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. The new inhalers, designed for patients with asthma and chronic obstructive pulmonary disease (COPD), will use Honeywell Solstice Air propellant which has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell’s Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDls). The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin.
Key Highlights
- Lupin to use Honeywell’s Solstice® Air as a next-generation propellant in pMDls.
- Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.
- Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD.
- The deal is subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin.
- Lupin is committed to delivering high-quality medicines while working towards a healthier, more sustainable future for patients and communities worldwide.